undamentalytics Newsletter
Sign in

Cardlytics, Inc. (CDLX) stock

Add to watchlist

Add holding +

NASDAQ: CDLX Nasdaq Advertising Next results ~November 5, 2026

Cardlytics, Inc. is a US-listed company in the advertising industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Cardlytics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 3 selling2 purchases and 16 sales by directors and officers, last 12 monthsInsider trades
  • Funds39 adding, 0 cuttingOf 5 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cardlytics files

Where Cardlytics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $179m, down 29.8% on a year earlier, a steeper fall than the 24.9% decline a quarter earlier. Free-cash-flow margin rose to 0.3% from -0.9% a year earlier. Operating margin widened to -49.4% from -69.5%. The diluted share count is up 17.1% on a year earlier, which dilutes existing holders. It passes 2 of our 5 financial-health checks.

Our model value for Cardlytics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Cardlytics, Inc.'s trailing-twelve-month revenue fell 29.8% year on year, with a free-cash-flow margin of 0.3%.

Current signal Revenue growth decelerating: TTM revenue growth slowed to -29.8% (-4.9pp vs the prior quarter), the 9th consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 20.0 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 4 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 29.8% over the last 12 months.
  • Loss-making. Operating margin is -49.4%: costs exceed revenue.
  • Share dilution. Diluted shares rose 17.1% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 94% and a beta of 1.7 against the S&P 500.
  • Growth easing. The growth rate is 4.9 points lower than a quarter earlier.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.81 against an average estimate of -$1.35: beat by 40.3%
Revenue
$37m, down 36.5% on a year earlier
Share reaction
-12.4% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
billings $61m to $67m (Q3 2026); revenue $34m to $39m (Q3 2026)
Next report
November 5, 2026; average EPS estimate -$1.04

Cardlytics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+16.6%
  • 1 week+25.8%
  • 1 month-18.0%
  • This year-82.0%
  • 1 year-89.3%
  • 5 years-99.8%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$179M
Operating margin
-49.4%
Net margin
-55.9%
EPS (TTM, diluted)
$-19.17

Growth

Revenue growth
−29.8%
Change in growth rate
−4.9 pts
Share count change
+17.1%

Cash

Free cash flow (TTM)
$463,000
FCF margin
0.3%
Stock pay % of revenue
10.7%

Earnings

Last results
August 5, 2026
Next results (est.)
November 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Results
  3. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cardlytics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Valuation multiples over time Market data may be delayed

At fiscal year end 20182019202020212022202320242025
Share price$108.30$628.60$1427.70$660.90$57.80$92.10$37.10$11.50
Market value$2.1bn$14.9bn$38.9bn$21.3bn$1.9bn$3.4bn$1.8bn$611m
+ Net debt (− = net cash)$7m−$104m−$63m−$3m$108m$166m$194m$160m
Enterprise value$2.1bn$14.8bn$38.8bn$21.3bn$2.0bn$3.5bn$2.0bn$771m
Multiples
Price / sales 13.7x70.9xn/m79.7x6.5x10.9x6.4x2.6x
Price / earnings ————————
Price / free cash flow —n/m—————69.3x
EV / EBITDA ————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

0 /100

Weak moat

How hard Cardlytics's competitive advantage looks for rivals to wear away, judged from 9 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -28.3% of total assets over 9 years.

  • Durability 10 / 20

    Operating margin has been a median -47.9%; its worst year was -129.4%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 2 of 9 years, at a median -10.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 85.0% over five years; stock-based pay has been a median 12.8% of revenue.

AI disruption exposure: High. In this industry, the core product is information work that AI systems increasingly perform. The score above includes a 15-point deduction for that exposure (15 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $37m and EPS of −$1.04 (range −$1.25 to −$0.83) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.31 +30% $149m −36%
Next −$3.29 −43% $161m +8%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −47.0% on 90 days ago. In the last 30 days, 0 analysts raised Cardlytics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Cardlytics, Inc., last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$4.35 Current fiscal year, 60 days ago: −$3.67 Current fiscal year, 30 days ago: −$4.35 Current fiscal year, 7 days ago: −$4.35 Current fiscal year, Now: −$2.31 −$2.31 Next fiscal year, 90 days ago: −$3.10 Next fiscal year, 60 days ago: −$2.70 Next fiscal year, 30 days ago: −$3.55 Next fiscal year, 7 days ago: −$3.55 Next fiscal year, Now: −$3.29 −$3.29

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$4.35−$3.10
60 days ago −$3.67−$2.70
30 days ago −$4.35−$3.55
7 days ago −$4.35−$3.55
Now −$2.31−$3.29

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.35 −$0.81 +40.3%
Mar 2026 −$2.13 −$1.10 +48.4%
Dec 2025 −$0.70 $0.30 +142.9%
Sept 2025 −$1.50 −$0.70 +53.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Revenue Q3 2026 $34m to $39m
    “Revenue $34.0 - $39.0 (27%) - (17%)” source
  • Billings Q3 2026 $61m to $67m Non-GAAP
    “Billings (1) $61.0 - $67.0 (27%) - (20%)” source
  • Adjusted Contribution Q3 2026 $20m to $23m Non-GAAP
    “Adjusted Contribution (2) $20.0 - $23.0 (22%) - (10%)” source
  • Adjusted EBITDA Q3 2026 $0m to $3m Non-GAAP
    “Adjusted EBITDA (2) $0 - $3.0 ($3.4) - ($0.4)” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

4 analysts, Oct 2026
Buy00%
Hold375%
Sell125%

Monthly trend

  1. Oct 2026314

Counts of recommendations published by analysts covering Cardlytics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
8.9%
of tradable shares
Days to cover
8.43
at average volume
Short interest, 1 month
−24%
to October 15, 2026
Held by institutions
30%
of shares
Held by insiders
5.3%
of shares
Employees
275
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −89.3%

$19.40 on October 31, 2025 to $2.08

ThenNowEffect
Revenue (last 12 months) $256m $179m −29.8%
P/S multiple 0.4x 0.1x −83.8%
Share count 5m 5m −5.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CDLX−54%−91%+59%−60%−69%−82%
Industry peers (median)+22%−54%+10%−10%−37%−10%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CDLX25%25%50%33%25%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CDLX−60%−95%−71%−85%−77%−90%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since February 9, 2018: 100% from February 12, 2021 to October 28, 2026. Getting back needed a 98138% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.60 – $19.00
From 52-week high
−89.1%
vs 50-day average
−30.4%
vs 200-day average
−66.2%
Volatility (1 year)
95%
Beta vs S&P 500
1.66

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±27.1%
After a week
4 up, 8 down
typical move ±25.1%
After a month
3 up, 9 down
typical move ±34.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −12.4% −0.4% +4.5% −9.5%
May 7, 2026 −19.5% +0.5% −18.6% −34.6%
March 4, 2026 −1.6% +0.1% −15.2% +36.3%
November 5, 2025 −27.4% −0.7% −13.5% −36.6%
August 6, 2025 −29.3% +0.7% −28.8% −49.3%
May 7, 2025 −11.6% +1.1% −4.2% −16.7%
March 12, 2025 +2.5% −0.8% +12.9% −30.7%
November 6, 2024 −13.2% +3.3% −17.7% −15.8%
August 7, 2024 −59.6% +1.6% −49.6% −53.1%
May 8, 2024 −39.8% +0.6% −39.1% −43.4%
March 14, 2024 +68.6% −0.9% +77.2% +52.8%
January 29, 2024 +39.3% +0.7% +20.1% +37.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Cardlytics, Inc.
$150M $200M $250M $300M $350M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $302.5M Revenue (TTM), FY23 Q4: $309.2M Revenue (TTM), FY24 Q1: $312.5M Revenue (TTM), FY24 Q2: $305.4M Revenue (TTM), FY24 Q3: $293.5M Revenue (TTM), FY24 Q4: $278.3M Revenue (TTM), FY25 Q1: $267.1M Revenue (TTM), FY25 Q2: $255.5M Revenue (TTM), FY25 Q3: $240.5M Revenue (TTM), FY25 Q4: $222.6M Revenue (TTM), FY26 Q1: $200.5M Revenue (TTM), FY26 Q2: $179.3M $179.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $302.5M
FY23 Q4 $309.2M
FY24 Q1 $312.5M
FY24 Q2 $305.4M
FY24 Q3 $293.5M
FY24 Q4 $278.3M
FY25 Q1 $267.1M
FY25 Q2 $255.5M
FY25 Q3 $240.5M
FY25 Q4 $222.6M
FY26 Q1 $200.5M
FY26 Q2 $179.3M
Revenue growth, TTM YoY Cardlytics, Inc.
-30% -20% -10% 0% 10% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -1.2% Revenue growth, TTM YoY, FY23 Q4: 3.6% Revenue growth, TTM YoY, FY24 Q1: 5.9% Revenue growth, TTM YoY, FY24 Q2: 3.1% Revenue growth, TTM YoY, FY24 Q3: -3.0% Revenue growth, TTM YoY, FY24 Q4: -10.0% Revenue growth, TTM YoY, FY25 Q1: -14.5% Revenue growth, TTM YoY, FY25 Q2: -16.3% Revenue growth, TTM YoY, FY25 Q3: -18.0% Revenue growth, TTM YoY, FY25 Q4: -20.0% Revenue growth, TTM YoY, FY26 Q1: -24.9% Revenue growth, TTM YoY, FY26 Q2: -29.8% -29.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -1.2%
FY23 Q4 3.6%
FY24 Q1 5.9%
FY24 Q2 3.1%
FY24 Q3 -3.0%
FY24 Q4 -10.0%
FY25 Q1 -14.5%
FY25 Q2 -16.3%
FY25 Q3 -18.0%
FY25 Q4 -20.0%
FY26 Q1 -24.9%
FY26 Q2 -29.8%
Operating margin (TTM) Cardlytics, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -137.3% Operating margin (TTM), FY23 Q4: -43.9% Operating margin (TTM), FY24 Q1: -54.6% Operating margin (TTM), FY24 Q2: -53.1% Operating margin (TTM), FY24 Q3: -98.9% Operating margin (TTM), FY24 Q4: -70.2% Operating margin (TTM), FY25 Q1: -68.8% Operating margin (TTM), FY25 Q2: -69.5% Operating margin (TTM), FY25 Q3: -40.7% Operating margin (TTM), FY25 Q4: -43.0% Operating margin (TTM), FY26 Q1: -46.3% Operating margin (TTM), FY26 Q2: -49.4% -49.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -137.3%
FY23 Q4 -43.9%
FY24 Q1 -54.6%
FY24 Q2 -53.1%
FY24 Q3 -98.9%
FY24 Q4 -70.2%
FY25 Q1 -68.8%
FY25 Q2 -69.5%
FY25 Q3 -40.7%
FY25 Q4 -43.0%
FY26 Q1 -46.3%
FY26 Q2 -49.4%
FCF margin (TTM) Cardlytics, Inc.
-10% -5% 0% 5% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -5.5% FCF margin (TTM), FY23 Q4: -0.3% FCF margin (TTM), FY24 Q1: -2.8% FCF margin (TTM), FY24 Q2: -3.4% FCF margin (TTM), FY24 Q3: -3.6% FCF margin (TTM), FY24 Q4: -3.7% FCF margin (TTM), FY25 Q1: 0.4% FCF margin (TTM), FY25 Q2: -0.9% FCF margin (TTM), FY25 Q3: -0.5% FCF margin (TTM), FY25 Q4: 4.0% FCF margin (TTM), FY26 Q1: 5.0% FCF margin (TTM), FY26 Q2: 0.3% 0.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -5.5%
FY23 Q4 -0.3%
FY24 Q1 -2.8%
FY24 Q2 -3.4%
FY24 Q3 -3.6%
FY24 Q4 -3.7%
FY25 Q1 0.4%
FY25 Q2 -0.9%
FY25 Q3 -0.5%
FY25 Q4 4.0%
FY26 Q1 5.0%
FY26 Q2 0.3%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 113 130 151 210 187 267 299 309 278 233 179
EBITDA −52 −14 −38 −13 −46 −93 −420 −109 −170 −77 −68
Operating income −56 −17 −41 −17 −54 −123 −458 −136 −195 −102 −89
Net income −76 −20 −53 −17 −55 −129 −465 −135 −189 −103 −100
Diluted EPS −$32.48 −$7.86 −$2.79 −$0.72 −$2.04 −$3.99 −$13.92 −$3.69 −$3.91 −$1.95 —
Growth (year on year)
Revenue — +15.6% +15.6% +39.6% −11.2% +42.9% +11.8% +3.6% −10.0% −16.2% −29.8%
Margins
EBITDA margin −46.1% −10.8% −25.0% −6.1% −24.7% −34.7% −140.8% −35.3% −61.0% −32.8% −37.6%
Operating margin −49.8% −13.1% −27.2% −8.2% −28.9% −45.9% −153.3% −43.9% −70.2% −43.6% −49.4%
Net margin −67.1% −15.1% −35.2% −8.1% −29.7% −48.1% −155.8% −43.6% −68.0% −44.4% −55.9%
Free-cash-flow margin −30.4% −17.9% −16.5% 1.5% −7.0% −15.6% −18.4% −0.3% −3.7% 3.8% 0.3%
Cash flow
Cash from operations −32 −22 −19 11 −8 −39 −54 −0 −9 9 1
Capital spending 2 1 6 8 5 3 1 1 2 0 0
Free cash flow −34 −23 −25 3 −13 −42 −55 −1 −10 9 0
Stock-based pay 3 5 27 16 32 50 45 41 40 28 19
Free cash flow after stock pay −38 −28 −52 −13 −45 −92 −100 −42 −51 −19 −19
Balance sheet
Cash 23 21 40 104 293 233 122 92 66 49 28
Total debt 0 57 47 0 230 230 230 258 259 209 184
Net debt (negative = net cash) −23 36 7 −104 −63 −3 108 166 194 160 156
Diluted shares 2m 3m 19m 24m 27m 32m 33m 36m 48m 53m —
Returned to shareholders
Buybacks — — — — 0 0 40 0 0 — —
Total returned — — — — 0 0 40 0 0 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · June 30, 2026
What it owns · $235m
Short-term assets $101mLonger-term assets $134m
What it owes, and who funded it · $251m
Short-term liabilities $62mLonger-term liabilities $188mShareholders' equity $-16m
  • Short-term assets cover short-term liabilities $101m of assets due within a year against $62m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $101m short-term assets against $188m of longer-dated liabilities.
  • More cash than debt $28m of cash against $184m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $532,000 of operating cash flow against $184m of debt.
  • Operating profit covers interest at least five times over Operating income of −$89m against −$10m of interest.

From Cardlytics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+17.1%
year over year
R&D spending
16.0%
of revenue
Days sales outstanding
138 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in advertising
Last 12 months unless stated CDLX FLNT HHS NCMI SWAG NEXN Median
Revenue, last 12 months $179m $202m $155m $249m $120m $365m $191m
Revenue growth, last 12 months −29.8% −12.0% −11.6% 5.8% 10.3% −0.2% −3.2%
Revenue growth, 3-year average −15.4% −15.3% −8.8% 8.3% 23.0% — 7.1%
Revenue growth, latest quarter −36.5% 8.4% −1.7% 12.7% 2.4% — 2.4%
Gross margin — 33.3% — 94.2% 29.7% 84.9% 40.3%
Operating margin −49.4% −7.4% −3.1% −7.1% −0.9% 8.9% −3.4%
Operating margin, 3-year average −57.3% −12.2% −0.6% −9.5% −1.9% — −3.6%
Net margin −55.9% −11.5% −3.7% −3.1% 0.0% 6.9% −2.7%
Cash from operations / revenue 0.3% −2.1% 0.8% 9.6% −3.1% 30.2% 2.2%
Free-cash-flow margin 0.3% −2.1% −0.9% 7.9% −3.6% 26.9% 3.2%
Free-cash-flow margin, 3-year average −1.3% 0.1% −1.9% 8.6% −2.8% — 7.9%
Stock pay / revenue 10.7% 2.0% 0.4% 3.1% 0.2% 4.9% 2.9%
Change in share count 17.1% 50.2% 0.9% −1.4% −0.5% −12.9% 6.8%

Median of all 28 companies we cover in advertising. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Cardlytic Direct $212M 91.0% ▼ 16.9%
Bridg Acquisition $20.9M 9.0% ▼ 7.7%
Products and services
Line of business Revenue YoY
Costper Redemption $129M ▲ 30.1%
Costper Served Sales $79.1M ▼ 47.8%
Bridg Subscription Revenue $20.9M ▼ 7.7%
Bridg Total Revenue $20.9M ▼ 7.7%
Cost Other $4M ▼ 16.3%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
United States $203M 87.0% ▼ 20.1%
United Kingdom $30.3M 13.0% ▲ 25.1%

From Cardlytics, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$5.7M
Institutions reporting
40
Positions opened / closed
39 / 0

Top buyers and sellers, Q2 2026: 39 institutions bought and 0 sold ; the biggest buyer was Vanguard Capital Management LLC (+219K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $981,568 219K 17.2% —
683 Capital Management, LLC $898,000 200K 15.7% —
Kps Global Asset Management Uk Ltd $547,255 122K 9.6% —
Worldly Partners Management, LLC $519,933 116K 9.1% —
Blackrock, Inc. $380,098 85K 6.7% —
Rbf Capital, LLC $359,245 80K 6.3% —
Geode Capital Management, LLC $263,293 59K 4.6% —
Quinn Opportunity Partners LLC $207,613 46K 3.6% —
Jane Street Group, LLC $177,540 40K 3.1% —
UBS Group AG $160,535 36K 2.8% —
Vanguard Fiduciary Trust Co $146,769 33K 2.6% —
Citadel Advisors LLC $128,400 29K 2.3% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cardlytics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $129,000 2 trades by 1 insider, last 12 months Insider sales History → $535,300 16 trades by 3 insiders · 0% under pre-set plans
Net ▼ $406,300 net selling
Insider Date Trade Shares Price Value
Gupta Amit Chief Executive Officer October 2, 2026 Sell 7,382 $2.53 $18,699
Gupta Amit Chief Executive Officer October 1, 2026 Sell 10,351 $2.71 $28,051
Gupta Amit Chief Executive Officer August 18, 2026 Sell 6,676 $4.03 $26,904
Gupta Amit Chief Executive Officer August 17, 2026 Sell 6,785 $3.97 $26,936
Gupta Amit Chief Executive Officer July 6, 2026 Sell 9,640 $4.39 $42,320
Lynton Nicholas Hollmeyer Chief Legal & Privacy Officer July 2, 2026 Sell 2,151 $4.40 $9,464
Gupta Amit Chief Executive Officer July 2, 2026 Sell 6,498 $4.40 $28,591
Evans David Thomas Chief Financial Officer May 18, 2026 Buy 50,000 $0.63 $31,500
Evans David Thomas Chief Financial Officer May 15, 2026 Buy 150,000 $0.65 $97,500
Gupta Amit Chief Executive Officer April 6, 2026 Sell 69,833 $1.19 $83,101
Gupta Amit Chief Executive Officer April 2, 2026 Sell 54,225 $1.04 $56,394
Lynton Nicholas Hollmeyer Chief Legal & Privacy Officer April 1, 2026 Sell 40,296 $0.99 $39,893

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 4, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 7, 2026
  • March 4, 2026
  • November 5, 2025
  • August 6, 2025
  • May 7, 2025

Recent SEC filings

Data status

When each part of this page on Cardlytics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cardlytics, Inc. in brief

What does Cardlytics, Inc. do?
Cardlytics, Inc. is a US-listed company in the advertising industry. Its financial year ends in December.
What is Cardlytics, Inc.'s stock ticker?
Cardlytics, Inc. trades under the ticker CDLX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cardlytics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cardlytics, Inc. reported revenue of $179M, 29.8% lower than a year earlier, according to its SEC filings.
What is Cardlytics, Inc.'s free cash flow?
Cardlytics, Inc.'s free-cash-flow margin is 0.3% of revenue over the trailing twelve months.
Who are Cardlytics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, 683 Capital Management, LLC and Kps Global Asset Management Uk Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cardlytics, Inc.'s market cap?
On December 31, 2025, Cardlytics, Inc.'s market capitalisation was about $611M and net debt of $160M. Market figures come from third-party market data and may be delayed.
Who are Cardlytics, Inc.'s competitors?
In our Advertising peer group, the companies closest to Cardlytics, Inc. are Fluent, Inc., Harte Hanks Inc, National Cinemedia, Inc., Stran & Company, Inc. and Nexxen International Ltd. The side-by-side comparison below sets their revenue, margins and growth against Cardlytics, Inc.'s.
Are insiders buying or selling Cardlytics, Inc. stock?
Over the last 12 months, Cardlytics, Inc.'s directors and officers reported 2 open-market purchases and 16 sales on Form 4. The insider trading page charts every trade.
When is Cardlytics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cardlytics, Inc. announces its own schedule.